← All trials
NCT05471076
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 22, 2022
- Primary completion
- Apr 14, 2023
- Completion date
- Jul 14, 2023
- First posted
- Jul 22, 2022
- Last posted
- Nov 22, 2022
- Enrollment
- 52
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- National Institutes of Health (NIH)Collaborator
- University of WashingtonStudy chair
- University of California, San FranciscoStudy chair
- Department of Health and Human ServicesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.